PDF icon Download PDF
Int J Angiol
DOI: 10.1055/a-2640-0775
Original Article

Investigation of the Survival Time of Patients Who Underwent Endovascular Treatment Due to Type 3 Aortic Dissection and Factors Affecting This Duration

Mehmet Işık 
1   Department of Cardiovascular Surgery, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye
,
Yalçın Günerhan 
1   Department of Cardiovascular Surgery, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye
,
Ömer Tanyeli 
1   Department of Cardiovascular Surgery, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye
,
Serkan Yıldırım 
1   Department of Cardiovascular Surgery, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye
,
Ali Demiray 
1   Department of Cardiovascular Surgery, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye
› Author Affiliations
Funding None.
› Further Information
   Permissions and Reprints
Preview

Abstract

Objective

This study aimed to analyze the survival time of patients who underwent thoracic endovascular aortic replacement (TEVAR) due to acute type 3 aortic dissection and to investigate comorbid conditions and dissection characteristics that affect survival time.

Materials and Methods

Between 2013 and 2023, 94 patients who underwent TEVAR for type 3 dissection were retrospectively investigated. Survival time and factors affecting this time (comorbidity and dissection characteristics) were analyzed.

Results

The most common comorbidities were hypertension (88%). There was no significant difference between the demographic data of surviving and deceased patients. During the follow-up period, 57% of the patients survived, and 43% of the patients died. The mean survival time after TEVAR was 20.1 (0–108) months among patients who died and 47.7 (2–120) months for patients who lived. The mean number of comorbidities was 2.13 in patients who died and 2.25 in patients who survived. Survival distribution according to the type of interventional procedure was 50% for partial closure of the subclavian artery, 38.1% for complete closure, and 66.2% for closure starting from the distal subclavian artery (p = 0.06). Survival rate was significantly higher in patients who underwent reintervention (p = 0.005). Mortality was 9.5% in the early period, 25.5% in the first year, 29.7% in the second year, 34% in the third year, and 39.3% in the first 5 years.

Conclusion

In our study, the survival rate was higher in patients who were followed regularly, and reintervention was applied when necessary. Therefore, we believe that undetected or untreated complications after TEVAR, rather than comorbid conditions, negatively affect survival more.

Keywords

TEVAR - PETTICOAT - type 3 dissection - De Bakey type 3 dissection - Stanford type B dissection

Ethical Approval

Permission was granted by the local ethics committee for the study protocol (2024/4791) and every patient provided written informed consent.


Authors' Contributions

M.I. contributed to study planning, manuscript writing, data collection, and overall supervision. Y.G. contributed to study planning, data collection, and supervision. Ö.T. and S.Y. were involved in study planning and supervision. A.D. contributed to study planning, data collection, and supervision.




Publication History

Article published online:
02 July 2025

© 2025. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA